To the Editor In an Original Investigation in a recent issue of JAMA Internal Medicine, Merkow and colleagues1 focused on the lack of clarity in cancer surveillance recommendations because of the prolongation of survival due to the innovative treatment development. They concluded that recommendations of cancer guidelines should be nonambiguous with the aim of optimizing care quality and resource use.